초록 ▼

Bioabsorbable biocompatible polymers which provide a good match between their properties and those of certain tissue structures are provided. The bioabsorbable biocompatible polymers can be prepared with tensile strengths, elongation to breaks, and/or tensile modulus (Young's modulus) values of the

Bioabsorbable biocompatible polymers which provide a good match between their properties and those of certain tissue structures are provided. The bioabsorbable biocompatible polymers can be prepared with tensile strengths, elongation to breaks, and/or tensile modulus (Young's modulus) values of the tissues of the cardiovascular, gastrointestinal, kidney and genitourinary, musculoskeletal, and nervous systems, as well as those of the oral, dental, periodontal, and skin tissues. Methods for processing the bioabsorbable biocompatible polymers into tissue engineering devices are also provided.

대표청구항 ▼

Bioabsorbable biocompatible polymers which provide a good match between their properties and those of certain tissue structures are provided. The bioabsorbable biocompatible polymers can be prepared with tensile strengths, elongation to breaks, and/or tensile modulus (Young's modulus) values of the

Bioabsorbable biocompatible polymers which provide a good match between their properties and those of certain tissue structures are provided. The bioabsorbable biocompatible polymers can be prepared with tensile strengths, elongation to breaks, and/or tensile modulus (Young's modulus) values of the tissues of the cardiovascular, gastrointestinal, kidney and genitourinary, musculoskeletal, and nervous systems, as well as those of the oral, dental, periodontal, and skin tissues. Methods for processing the bioabsorbable biocompatible polymers into tissue engineering devices are also provided. laim 1, wherein said cartilage repair matrix comprises a collagen-containing material selected from the group consisting of an autograft tissue, an allograft tissue, and a xenograft tissue. 11. The product of claim 1, wherein said cartilage repair matrix comprises collagen from bovine tendon. 12. The product of claim 1, wherein said matrix is configured as a tapered shape, and wherein said matrix is cross-linked. 13. The product of claim 12, wherein said cartilage repair matrix is cross-linked with an aldehyde. 14. The product of claim 1, wherein said mixture of proteins further comprises one or more serum proteins. 15. The product of claim 14, wherein said serum proteins are selected from the group consisting of albumin, transferrin, α2-Hs GlycoP, IgG, α1-antitrypsin, β2-microglobulin, Apo A1 lipoprotein (LP) and Factor XIIIb. 16. The product of claim 14, wherein said serum proteins are selected from the group consisting of albumin, transferrin, Apo A1 LP and Factor XIIIb. 17. The product of claim 1, wherein said cartilage-inducing composition is at a concentration of from about 0.5% to about 33% by weight of said product. 18. The product of claim 1, wherein said cartilage-inducing composition is at a concentration of from about 1% to about 20% by weight of said product. 19. The product of claim 1, wherein said mixture of proteins is bone protein (BP). 20. The product of claim 1, wherein said TGFβ superfamily proteins comprise from about 0.5% to about 25% of said mixture of proteins. 21. The product of claim 1, wherein said TGFβ superfamily proteins comprise from about 1% to about 10% of said mixture of proteins. 22. The product of claim 1, wherein said bone matrix proteins comprise from about 40% to about 98% of said mixture of proteins. 23. The product of claim 1, wherein said bone matrix proteins comprise from about 80% to about 98% of said mixture of proteins. 24. The product of claim 1, wherein said FGF-I comprises from about 0.1% to about 10% of said mixture of proteins. 25. The product of claim 1, wherein said lesion is within meniscal cartilage selected from the group consisting of vascular meniscal cartilage and avascular meniscal cartilage. 26. The product of claim 1, wherein said cartilage inducing composition has an identifying characteristic selected from the group consisting of an ability to induce cellular infiltration, an ability to induce cellular proliferation, and an ability to induce cellular differentiation to type II collagen-producing chondrocytes. 27. The product of claim 1, wherein said cartilage-inducing composition further comprises a glycosaminoglycan that non-covalently attaches to said proteins in said composition. 28. The product of claim 1, wherein said cartilage repair matrix comprises a material selected from the group consisting of poly(lactic acid), poly(glycolic acid), type I collagen, type II collagen, type IV collagen and hyaluronic acid. 29. The product of claim 1, wherein said matrix is configured as a sheet, and wherein said sheet has a thickness of from about 0.1 mm to about 3 mm. 30. The product of claim 1, wherein said matrix is configured as a sheet, and wherein said sheet has a thickness of from about 0.5 mm to about 2 mm. 31. The product of claim 1, wherein said matrix is configured as a sheet, and wherein said sheet is prepared from an aqueous dispersion of from about 0.2% to about 4% collagen by weight. 32. The product of claim 1, wherein said matrix is configured as a sheet, and wherein said sheet is prepared from an aqueous dispersion of from about 0.5% to about 3% collagen by weight. 33. The product of claim 1, wherein said cartilage repair matrix is configured as a sheet, and wherein said sheet is porous, having a pore diameter of from about 10 μm to about 100 μm. 34. The product of claim 1, wherein said matrix is configured as a tapered shape which varies in thickness from about 0.5 mm to about 3 mm at its thinnest region to from about 4 mm to about 10 mm at its th ickest region. 35. The product of claim 1, wherein said matrix is configured as a tapered shape, and wherein said matrix has a density of from about 0.07 to about 0.5 grams matrix per cm3. 36. The product of claim 1, wherein said matrix is configured as a tapered shape, and wherein said matrix has a density of from about 0.1 to about 0.25 grams matrix per cm3. 37. The product of claim 1, wherein said matrix is configured as a tapered shape, and wherein said cartilage repair matrix is porous, having a pore diameter of from about 50 μm to about 500 μm. 38. The product of claim 1, wherein said matrix is configured as a tapered shape, and wherein said cartilage repair matrix comprises a porous ground substance composite which includes collagen. 39. The product of claim 12, wherein said matrix is cross-linked by an agent selected from the group consisting of formaldehyde, glutaraldehyde, dimethyl suberimidate, carbodiimides, multi-functional epoxides, succinimidyls, poly(glycidyl ether), diisocyanates, acyl azide, tris(hydroxymethyl)phosphine, ascorbate-copper, glucose-lysine and photo-oxidizers. 40. The product of claim 12, wherein said matrix is cross-linked by a method selected from the group consisting of: ultraviolet irradiation and dehydrothermal treatment. 41. The product of claim 1, wherein said cartilage-inducing composition is contained on or within said cartilage repair matrix by a method selected from the group consisting of freeze-drying said composition onto a surface of said matrix and suspension within said cartilage repair matrix of a delivery formulation containing said composition. 42. The product of claim 1, wherein said FGF-I comprises from about 0.05% to about 25% of said mixture of proteins. 43. A method for repair of meniscal cartilage lesions, comprising implanting and fixing into a meniscal cartilage lesion a product comprising: a. a cartilage repair matrix; and b. a cartilage-inducing composition contained on or within said matrix comprising a mixture of proteins comprising: i. transforming growth factor β (TGFβ) superfamily proteins: TGFβ1, TGFβ2, TGFβ3, bone morphogenetic protein (BMP)-2, BMP-3, BMP4, BMP-5, BMP-6, BMP-7, and cartilage-derived morphogenetic protein (CDMP); wherein said TGFβ superfamily proteins comprise from about 0.1% to about 50% of said mixture of proteins; ii. bone matrix proteins: osteocalcin, osteonectin, bone sialoprotein (BSP), lysyloxidase, and cathepsin L pre; wherein said bone matrix proteins comprise from about 20% to about 98% of said mixture of proteins; and, iii. fibroblast growth factor-I (FGF-I), wherein said FGF-I comprises from about 0.01% to about 50% of said mixture of proteins. 44. The method of claim 43, wherein said lesion is a tear and wherein said matrix is configured as a sheet, wherein said step of implanting comprises inserting said product directly into said tear. 45. The method of claim 43, wherein said product is fixed into said lesion by an attachment means selected from the group consisting of bioresorbable sutures, non-resorbable sutures, press-fitting, arrows, nails, and T-fix suture anchor devices. 46. The method of claim 43, wherein said lesion is a vascular meniscus lesion. 47. The method of claim 43, wherein said lesion is an avascular meniscus lesion. 48. The method of claim 43, wherein said lesion is a meniscal radial tear. 49. The method of claim 43, wherein said lesion is a meniscal bucket handle tear. 50. The method of claim 43, wherein said lesion is a meniscal segmental defect. 51. A product for repair of vascular and avascular meniscus tears, comprising: a. a cartilage repair matrix comprising collagen selected from the group consisting of: a matrix configured as a sheet which conforms to a meniscal radial tear, a matrix configured as a sheet which conforms to a meniscal bucket handle tear, a matrix configured as a sheet which conforms to a meniscal longitudinal tear; and b. a cartilage-inducing